Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jörg U. Schmohl, Martin Felices, Felix Oh, Alexander J. Lenvik, Aaron M. Lebeau, Jayanth Panyam, Jeffrey S. Miller, Daniel A. Vallera
Cancer Res Treat. 2017;49(4):1140-1152.   Published online 2017 Feb 20     DOI:
Citations to this article as recorded by Crossref logo
Emerging trends in bispecific antibody and scaffold protein therapeutics
Petra Verdino, Shane Atwell, Stephen J Demarest
Current Opinion in Chemical Engineering.2018; 19: 107.     CrossRef
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
Sarah Cooley, Peter Parham, Jeffrey S. Miller
Blood.2018; 131(10): 1053.     CrossRef
Bispecific antibodies in cancer immunotherapy
Eva Dahlén, Niina Veitonmäki, Per Norlén
Therapeutic Advances in Vaccines and Immunotherapy.2018; 6(1): 3.     CrossRef
Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics
Martin Dalziel, Stephen A Beers, Mark S Cragg, Max Crispin
Glycobiology.2018; 28(9): 697.     CrossRef
The role of CD133 in cancer: a concise review
Paige M. Glumac, Aaron M. LeBeau
Clinical and Translational Medicine.2018;[Epub]     CrossRef
Advances and challenges in therapeutic monoclonal antibodies drug development
Mariana Lopes dos Santos, Wagner Quintilio, Tania Maria Manieri, Lilian Rumi Tsuruta, Ana Maria Moro
Brazilian Journal of Pharmaceutical Sciences.2018;[Epub]     CrossRef
Developmental and Functional Control of Natural Killer Cells by Cytokines
Yang Wu, Zhigang Tian, Haiming Wei
Frontiers in Immunology.2017;[Epub]     CrossRef
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis, Daniel A. Vallera, Jeffrey S. Miller, Martin Felices
Seminars in Immunology.2017; 31: 64.     CrossRef